Creating a database for patients at risk of interstitial lung disease
Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease
This study is trying to create a database to help track and monitor patients at risk for interstitial lung disease so they can catch it early and manage it better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 412 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 1 site (Graz) |
| Trial ID | NCT04707781 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a clinical database for patients who are at risk for interstitial lung disease (ILD) and to implement a prospective screening program for early detection of ILD. Participants will undergo chest CT scans to monitor their lung health. The study will collect data to better understand the progression of ILD in patients with known systemic diseases that predispose them to this condition. By gathering this information, researchers hope to improve early diagnosis and management of ILD.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with known systemic diseases that increase their risk for interstitial lung disease.
Not a fit: Patients under 18 years old or those with comorbidities that severely limit life expectancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of interstitial lung disease in at-risk patients.
How similar studies have performed: While similar observational studies have been conducted, this specific approach to creating a comprehensive database for ILD risk assessment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: ≥ 18 years * patients with a known systemic disease bearing a risk for ILD * signed informed consent (for prospective part) Exclusion Criteria: * Age \< 18 years * comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)
Where this trial is running
Graz
- Medical University of Graz, Department of Internal Medicine, Division of Pulmonology — Graz, Austria (Recruiting)
Study contacts
- Study coordinator: Gabor Kovacs, MD
- Email: gabor.kovacs@klinikum-graz.at
- Phone: +43-316-385
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.